Neurocrine Biosciences, Inc. (NBIX)
Develops medicines treating brain, psychiatric, hormone, and immune disorders.
$182.15+0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+41.3%
The outlook
Neurocrine Biosciences is trading near its 52-week highs with broad analyst support rated as Strong Buy. The stock sits above both its 50- and 200-day moving averages, and the average analyst price target sits roughly 11% above the current price. At a trailing P/E of 28.1, the valuation reflects premium pricing relative to historical biotech norms.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 27 analysts
Price trendAbove its 50- & 200-day averages
52-week range100% of the way from its 52-week low to high
Price targetAvg target +11% vs current price
Analyst price target
~12-month · 27 analysts$202.17average target+11.0% vs now
Now $182.15
Low $170.00High $250.65
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$18.32B
52-wk high
$182.25
52-wk low
$122.14
50-day avg
$165.62
200-day avg
$145.09
Trailing P/E
28.1